Effect of the Antioxidant Lipoic Acid in Aortic Phenotype in a Marfan Syndrome Mouse Model

Table 2

Evolution of structural aorta remodeling in WT and MFS mice with 1, 3, and 6 months of age.

	WT1 ()	MFS1 ()	WT3 ()	MFS3 ()	WT6 ()	MFS6 ()
Aortic arch
Thickness (mm^2)	29 ± 1	32 ± 2	28 ± 2	36 ± 2	28 ± 1	40 ± 3^a,b,c
Total CVF (%)	8 ± 1	8 ± 1	10 ± 1	10 ± 1	11 ± 2	23 ± 6^b–f
Collagen I/III ratio	1.0	2.4 ± 0.6^d	1.1 ± 0.1^g	3.6 ± 1.2^d,e	1.0 ± 0.1^g,h	12.1 ± 4.1^f,i–l
EFD (number/mm^2)	0.10 ± 0.01	0.80 ± 0.08^i	0.10 ± 0.02^f	0.76 ± 0.04^i,j	0.10 ± 0.03^f,l	1.30 ± 0.08^i–k
FBN1 (area %)	100.0	28 ± 9^i	99 ± 1^f	32 ± 6^i,j	101 ± 1^f,l	33 ± 5^i–k
Thoracic aorta
Thickness (mm^2)	21 ± 1	21 ± 1	23 ± 1	22 ± 2	25 ± 1	26 ± 4
Total CVF (%)	9 ± 2	8 ± 1	14 ± 1	13 ± 2	15 ± 2	19 ± 1 ^b–d,g,m
Collagen I/III ratio	1.0	1.9 ± 0.3^d	0.9 ± 0.1^g	2.2 ± 0.5^d,e	1.0 ± 0.1^g,h	3.1 ± 0.7^f,i–k
EFD (number/mm^2)	0.12 ± 0.01	0.46 ± 0.06^a	0.11 ± 0.03^n	0.37 ± 0.08^a,b	0.10 ± 0.02^m,n	0.92 ± 0.13^f,i–l
FBN1 (area %)	100.0	25 ± 1^i	101 ± 1^f	21 ± 4^i,j	100 ± 1^f,l	48 ± 5^i–k
Abdominal aorta
Thickness (mm^2)	15 ± 2	17 ± 1^i	22 ± 1^f	21 ± 2^g,i,j	23 ± 1^f,l	34 ± 3^i–l
Total CVF (%)	10 ± 2	8 ± 1	11 ± 1	12 ± 2	10 ± 1	31 ± 2^f,i,j,m,o
Collagen I/III ratio	1.0	2.0 ± 0.3^a	1.0 ± 0.1	3.1 ± 0.9^a,b	1.1 ± 0.1^b,n	11.7 ± 3.2^g,i–k,n
EFD (number/mm^2)	0.10 ± 0.01	0.50 ± 0.10^d	0.10 ± 0.01^g	0.62 ± 0.14^i,j	0.10 ± 0.01^f,l	0.95 ± 0.19^i–k
FBN1 (area %)	100.0	23 ± 5^i	100 ± 1^f	21 ± 3^i,j	100 ± 1^f,l	44 ± 6^d,e,o

WT: wild type; MFS: Marfan syndrome; 1: 1 month of age; 3: 3 months of age; 6: 6 months of age; CVF: collagen volume fraction; EFD: elastic fiber disruptions; FBN 1: fibrillin-1; ^a versus WT1; ^b versus WT3; ^c versusWT6; ^d versus WT1; ^e versus WT3; ^f versus MFS1; ^g versus MFS1; ^h versusMFS3; ⁱ versus WT1; ^j versus WT3; ^k versus WT6; ^l versus MFS3; ^m versus MFS3; ⁿ versus MFS1; ^o versus WT6.